

IN THE SPECIFICATION:

Please replace paragraph [9] with the following rewritten paragraph:

1
--Atorvastatin calcium (sold in the U.S. under the trademark LIPITOR®) is susceptible to a low pH environment and can degrade to the corresponding lactone in an acidic environment. Mills et al. have stated in U.S. Patent No. 5,686,104 that this and similar compounds in an oral pharmaceutical formulation for the treatment of hypercholesterolemia or hyperlipidemia are stabilized by combination with at least one basic inorganic pharmaceutically acceptable calcium, magnesium, aluminum or lithium salt. Examples of these salts are calcium carbonate, calcium hydroxide, magnesium carbonate, magnesium hydroxide, magnesium silicate, magnesium aluminate, aluminum magnesium hydroxide or lithium hydroxide. Calcium hydroxide is disclosed as the preferred alkaline earth stabilizing agent. Thus, as in U.S. Patent No. 5,180,589, the stabilizing agents disclosed in U.S. Patent No. 5,686,104 are basic inorganic pharmaceutically acceptable salts.--

Attached hereto is a mark-up version of the changes made to the specification by the current amendment. The Attached page is captioned "**Version with Markings to Show Changes Made.**"

REMARKS

The specification was amended to correct a typographical error. Applicant submits that no new matter was added.

Claims 1-39 are pending and are under examination.